Payment overview · 2025
General Payments
$882.24
65 reported records · 19 companies
Healthcare provider profile · identity verified
James Shumate, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · JACKSONVILLE, NC · NPI 1649267220
Verified facts
What the public records show
CMS Open Payments records show James Shumate, D.O. received $882.24 in general payments during 2025 across 65 reported records.
ABBVIE INC. accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rybelsus, Trelegy Ellipta, Veozah, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Enbrel by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Veozah by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $202.09 | 22.9% | 25 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $147.03 | 16.7% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $103.67 | 11.8% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $66.52 | 7.5% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $41.90 | 4.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.08 | 4.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.72 | 3.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.59 | 3.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $26.39 | 3.0% | 1 | 2025 |
| Exeltis, USA Inc. | Unresolved — no canonical attribution shown | $24.28 | 2.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.75 | 2.6% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $22.33 | 2.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.24 | 2.3% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $19.66 | 2.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.55 | 2.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.55 | 2.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.95 | 1.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.29 | 1.9% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $14.65 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $882.24 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $126.63 | 19 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $126.63 | 19 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $81.00 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $79.82 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $79.82 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $64.58 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.54 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $41.90 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $40.80 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.08 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $38.08 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.72 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.59 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.59 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $26.39 | 1 | 2025 |
Source payment records
|
|||||
| SLYND Normalized: slynd |
Drug | Exeltis, USA Inc. | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $10.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 134 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 62 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
98 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 468 | 100 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 341 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 324 | 74 |
| Gabapentin | Gabapentin | 304 | 60 |
| Oxycodone Hcl | Oxycodone Hcl | 280 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 266 | 52 |
| Lisinopril | Lisinopril | 252 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 233 | 47 |
| Omeprazole | Omeprazole | 231 | 56 |
| Furosemide | Furosemide | 201 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 190 | 43 |
| Alprazolam | Alprazolam | 182 | 23 |
| Montelukast Sodium | Montelukast Sodium | 177 | 30 |
| Losartan Potassium | Losartan Potassium | 170 | 41 |
| Pregabalin | Pregabalin | 164 | 25 |
| Metformin Hcl | Metformin Hcl | 156 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 37 |
| Sertraline Hcl | Sertraline Hcl | 147 | 21 |
| Tramadol Hcl | Tramadol Hcl | 145 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 139 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 28 |
| Jardiance | Empagliflozin | 134 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 131 | 20 |
| Ozempic | Semaglutide | 119 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 111 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 23 |
| Trazodone Hcl | Trazodone Hcl | 110 | 27 |
| Famotidine | Famotidine | 107 | 24 |
| Lorazepam | Lorazepam | 107 | 13 |
| Clonazepam | Clonazepam | 105 | suppressed |
| Ibuprofen | Ibuprofen | 104 | 29 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 99 | suppressed |
| Eliquis | Apixaban | 98 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 95 | 14 |
| Meloxicam | Meloxicam | 93 | 19 |
| Potassium Chloride | Potassium Chloride | 88 | 19 |
| Prednisone | Prednisone | 85 | 44 |
| Diazepam | Diazepam | 76 | 16 |
| Temazepam | Temazepam | 74 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 20 |
| Metformin Hcl Er | Metformin Hcl | 64 | 14 |
| Celecoxib | Celecoxib | 62 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | 13 |
| Linzess | Linaclotide | 62 | suppressed |
| Mirtazapine | Mirtazapine | 61 | 13 |
| Xtampza Er | Oxycodone Myristate | 59 | suppressed |
| Primidone | Primidone | 58 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 57 | 12 |
| Ondansetron Odt | Ondansetron | 56 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 54 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 52 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 12 |
| Simvastatin | Simvastatin | 52 | 13 |
| Allopurinol | Allopurinol | 51 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 51 | suppressed |
| Bupropion Xl | Bupropion Hcl | 50 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 50 | suppressed |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Januvia | Sitagliptin Phosphate | 48 | 12 |
| Carvedilol | Carvedilol | 46 | 12 |
| Ezetimibe | Ezetimibe | 46 | suppressed |
| Valsartan | Valsartan | 43 | suppressed |
| Trulicity | Dulaglutide | 42 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 14 |
| Promethazine Hcl | Promethazine Hcl | 38 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Methadone Hcl | Methadone Hcl | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Telmisartan | Telmisartan | 36 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 31 | 22 |
| Clobetasol Propionate | Clobetasol Propionate | 31 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | suppressed |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | 11 |
| Phenobarbital | Phenobarbital | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Premarin | Estrogens, Conjugated | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 24 | suppressed |
| Movantik | Naloxegol Oxalate | 24 | suppressed |
| Nystatin | Nystatin | 24 | 14 |
| Topiramate | Topiramate | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Estradiol | Estradiol | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Steglujan | Ertugliflozin/Sitagliptin Phos | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Veozah | Fezolinetant | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | suppressed |
| Enbrel | Etanercept | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Pro Comfort Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Fentanyl | Fentanyl | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $882.24 · 65 records | ABBVIE INC. | AREXVY, BEYFORTUS, BREZTRI, CAPLYTA, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FREESTYLE LIBRE 3, JARDIANCE, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PRECIVITYAD2, QULIPTA, REPATHA, Rybelsus, SHINGRIX, SLYND, Symbravo, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error